Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

Yonsei Medical Journal

Volumn 47, Issue 6, 2006, Pages 793-798

  Kim, Jie Hyun ^a   Han, Kwang Hyub ^a   Lee, Kwan Sik ^a   Park, Young Nyun ^a   Ahn, Sang Hoon ^a   Chon, Chae Yoon ^a   Moon, Young Myoung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis C; Interferons; Long term effects; Ribavirin

Indexed keywords

INTERMAX A; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD TOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; WEAKNESS;

EID: 33845927812     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.6.793     Document Type: Article

References (17)

1. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
4. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-100.
5. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29:1596-601.
6. Deuffic S, Poynard T, Valleron AJ. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 1999;6:411-3.
7. Huh K, Choi SY, Whang YS, Lee DS. Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J Korean Med Sci 1998;13:306-10.
8. Perez R, Jimenez M, Crespo J, Diago M, Enriquez J, Vaquero P, et al. Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. J Viral Hepat 2003; 10: 437-45.
9. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
10. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999;46:3216-22.
11. Horiike N, Fujisawa T, Michitaka K, Tada K, Masumoto T, Iuchi H, et al. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep 1998;5:1171-4.
12. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
13. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36(5 Suppl 1):S114-20.
14. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1): 5294-302.
15. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 88:58-65.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribarivin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
17. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.